Abdullah .

Dr. Abdullah .

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2024 in International Journal of Cardiology Cardiovascular Risk and Prevention
Verified
Journal Article
Open access
HSHumza Saeed
Humza Saeed
MAM.B.B.S. Abdullah
M.B.B.S. Abdullah
INIrum Naeem
Irum Naeem
AZAmna Zafar
Amna Zafar
BABilal Ahmad
Bilal Ahmad
AGAman Goyal
Aman Goyal
Heart Failure (HF) and Diabetes Mellitus (DM) often coexist, and each condition independently increases the likelihood of developing the other. While there has been concern regarding the increasing burden of disease for both conditions individually over the last decade, a comprehensive examination of mortality trends and demographic and regional disparities needs to be thoroughly explored in the United States (US). This study analyzed death certificates from the CDC WONDER database, focusing on mortality caused by the co-occurrence of HF and DM in adults aged 75 and older from 1999 to 2020. Age-adjusted mortality rates (AAMRs) and annual percent changes (APCs) were computed and categorized by year, gender, race, census region, state, and metropolitan status. A total of 663,016 deaths were reported in patients with coexisting HF and DM. Overall, AAMR increased from 154.1 to 186.1 per 100,000 population between 1999 and 2020, with a notable significant increase from 2018 to 2020 (APC: 11.30). Older men had consistently higher AAMRs than older women (185 vs. 135.4). Furthermore, we found that AAMRs were highest among non-Hispanic (NH) American Indian or Alaskan natives and lowest in NH Asian or Pacific Islanders (214.4 vs. 104.1). Similarly, AAMRs were highest in the Midwestern region and among those dwelling in non-metropolitan areas. Mortality from HF and DM has risen significantly in recent years, especially among older men, NH American Indian or Alaska Natives, and those in non-metropolitan areas. Urgent policies need to be developed to address these disparities and promote equitable healthcare access.

11 April 2025 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
A.Abdullah .
Abdullah .
BABazil Azeem
Bazil Azeem
MSMomina Riaz Siddiqui
Momina Riaz Siddiqui
Samiullah ShaikhSamiullah Shaikh
Samiullah Shaikh
ASAmmad Sattar
Ammad Sattar
HSHumza Saeed
Humza Saeed

4 February 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AGAman Goyal
Aman Goyal
HSHumza Saeed
Humza Saeed
WSWania Sultan
Wania Sultan
ASAjeet Singh
Ajeet Singh
A.Abdullah .
Abdullah .
WAWael AlJaroudi
Wael AlJaroudi
Background: Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) greatly influence morbidity and mortality, with COPD patients frequently suffering from cardiovascular comorbidities like coronary heart disease and stroke. This study analyzes mortality trends and disparities among individuals in the United States (US) affected by both CVD and COPD. Methods: This study analyzed death certificates from the CDC WONDER database for individuals aged 25 and older who died between 1999 and 2020 with both CVD (ICD I00-I99) and COPD (ICD J41-J44). Age-adjusted mortality rates (AAMRs) and annual percent change (APC) were calculated by year, sex, age group, race/ethnicity, geographic region, and urbanization status. Results: Between 1999 and 2020, there were 3,590,124 reported deaths due to coexisting CVD and COPD, with overall AAMR slightly changing from 82.2 to 81.2 per 100,000 population, and a notable rise from 2018 to 2020 (APC: 5.28; 95% CI: 1.83 to 7.22) coinciding with the onset of COVID-19 pandemic. A similar surge in mortality was observed across multiple demographic subgroups, particularly among older adults. Disparities across age groups, sex, race, and geographic location were also observed in the mortality rates due to CVD and COPD. When analyzed by age group, older adults exhibited the highest AAMR at 824.1. Men had higher AAMRs than women (96.5 vs. 60.7). Ethnoracial analysis showed that non-Hispanic (NH) White individuals had the highest AAMRs (82.0), followed by NH American Indian or Alaska Native (74.5), NH Black (63.6), Hispanic (38.1), and NH Asian or Pacific Islander (25.1) individuals. Additionally, non-metropolitan areas had higher AAMRs compared to metropolitan areas (96.2 vs. 70.9). Conclusions: The findings suggest that mortality rates for CVD and COPD have increased in recent years, coinciding with the onset of the COVID-19 pandemic, which may have exacerbated outcomes in vulnerable populations. The study highlights the need for targeted interventions to address the overlapping impacts of CVD and COPD, especially in high-risk groups.

25 February 2025 in Oncologie
Verified
Journal Article
Open access
PDF file
BABiruk Demisse Ayalew
Biruk Demisse Ayalew
A.Abdullah .
Abdullah .
SKSaim Mahmood Khan
Saim Mahmood Khan
ZAZemichael Getu Alemayehu
Zemichael Getu Alemayehu
MTMikiyas Gifawosen Teferi
Mikiyas Gifawosen Teferi
MHMuhidin Ibrahim Hundisa
Muhidin Ibrahim Hundisa
Theranostics is a technique used in precision oncology to combine focused treatments with diagnostic imaging, thereby enabling tailored cancer treatment. Using modern imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), Theranostics guarantees accurate tumor diagnosis and tailored treatment planning. Radiopharmaceuticals, such as Lutetium-177 (Lu-177) and prostate-specific membrane antigen (PSMA)-targeted therapies, have demonstrated significant clinical enhancements in progression-free and overall survival rates relative to traditional treatments, especially in prostate cancer and neuroendocrine tumors. Emerging technologies such as nanotheranostics and artificial intelligence (AI)-driven tools are enhancing the precision and efficacy of these treatments. However, the widespread application of theranostics is impeded by tumor heterogeneity, elevated prices, and restricted accessibility. Increased research and funding are necessary to address these issues and fully actualize theranostics’ potential to revolutionize cancer detection and therapy. To highlight the above challenges, this review examines diagnostic imaging and therapy advancements, focusing on clinical applications and technologies such as nanotechnology and AI-driven methods.

18 November 2024 in Endoscopy International Open
Verified
Journal Article
Open access
PDF file
SMStefan Mitev
Stefan Mitev
HSHumza Saeed
Humza Saeed
CRCh Faizan Rasheed
Ch Faizan Rasheed
A.Abdullah .
Abdullah .
SMStefan Murvakov
Stefan Murvakov
ZSZoya Spassova
Zoya Spassova
Texture and color enhancement imaging (TXI) is a novel optical technology designed to improve visibility during endoscopy by highlighting subtle differences in morphology and color. This systematic review and meta-analysis aimed to determine whether TXI, compared with conventional white light imaging (WLI), can improve important colonoscopy quality indicators, specifically the adenoma detection rate (ADR) and adenomas per colonoscopy (APC). We searched PubMed, EMBASE, and the Cochrane Central for studies comparing TXI to WLI in patients undergoing colonoscopy for any indication. Risk ratios (RRs) and mean differences (MDs) were computed using a random-effects model. We included 1541 patients from three studies, of which two were randomized controlled trials (RCTs). TXI was used in 775 patients (50.3%). Indications for colonoscopy varied, including positive fecal immunochemical test (FIT), surveillance, and diagnostic workup for abdominal symptoms. In the pooled data, TXI significantly increased both ADR (57,8% versus 43.6%; RR 1.32; 95% confidence interval [CI] 1.20-1.46; P < 0.001; I2 = 0%) and APC (MD 0.50; 95% CI 0.37-0.64; P < 0.001; I2 = 0%), compared with WLI. Furthermore, TXI was more effective at detecting nonpolypoid/flat adenomas, proximal/right-sided adenomas, and adenomas ≥ 10 mm in size. Colonoscopies with TXI had shorter withdrawal times. Our meta-analysis demonstrates that TXI significantly improves detection of colorectal adenomas in patients undergoing colonoscopy for various indications. TXI has the potential to improve overall quality of colonoscopy and contribute to colorectal cancer prevention. Received: 16 July 2024 Accepted after revision: 13 November 2024 Accepted Manuscript online: 18 November 2024 Article published online: 13 January 2025 © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

7 August 2025 in JMIR Diabetes
Verified
Journal Article
Open access
AHAsad Zaman Hashmi
Asad Zaman Hashmi
Ali Shan HafeezAli Shan Hafeez
Ali Shan Hafeez
AFAbdul Rafae Faisal
Abdul Rafae Faisal
MFMuhammad Faizan
Muhammad Faizan
MHMohammad Abdullah Humayun
Mohammad Abdullah Humayun
ADArkadeep Dhali
Arkadeep Dhali
Background: Pneumonia is the most common respiratory tract infection among patients with diabetes, affecting individuals across all age groups and sexes. Objective: This study aims to examine demographic trends in mortality among patients diagnosed with both diabetes mellitus (DM) and pneumonia. Methods: Deidentified death certificate data for DM- and pneumonia-related deaths in adults aged 25 years and older from 1999 to 2022 were obtained from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database. Age-adjusted mortality rates (AAMRs) per 1,000,000 population were calculated. The Joinpoint Regression Program was used to evaluate annual percentage changes (APCs) in mortality trends, with statistical significance set at P<.05. This study adhered to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for reporting. Results: Between 1999 and 2022, a total of 425,777 deaths were recorded from DM and pneumonia. The overall AAMR declined significantly (P=.001) from 98.73 in 1999 to 49.17 in 2016 (APC –4.68), and then surged to 97.66 by 2022 (APC 23.55). Men consistently experienced higher mortality than women throughout the study period. Male AAMR rose from 62.61 in 2016 to 127.05 in 2022 (APC 24.88), while female AAMR increased from 41.05 in 2017 to 75.25 in 2022 (APC 27.60). Race-based analysis demonstrated that American Indian or Alaska Native populations had the highest mortality rates among racial groups. Non-Hispanic White individuals exhibited a significant decline in AAMR (P=.002) from 89.76 in 1999 to 44.19 in 2017 (APC −4.58), followed by an increase to 83.11 by 2022 (APC 25.25). Adults aged 65 years or older bore the highest mortality burden, with rates declining steadily to 206.9 in 2017 (APC –5.15) before rising sharply to 371.3 in 2022 (APC 20.01). Nonmetropolitan areas consistently exhibited higher mortality than metropolitan areas, with particularly steep increases after 2018 (APC 64.42). Type-specific mortality revealed that type 1 DM AAMRs declined from 9.2 in 1999 to 1.4 in 2015 (APC –11.94) before rising again. By contrast, type 2 DM AAMRs surged drastically after 2017, peaking at 62.2 in 2020 (APC 58.74) before partially declining to 41.6 by 2022. Conclusions: DM is associated with an increased risk of mortality following pneumonia, particularly among men, older adults, and American Indian populations. Strengthening health care interventions and policies is essential to curb the rising mortality trend in these at-risk groups.